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Abelcet was discontinued in 14/19 patients, mainly due to renal toxicity, increase in bilirubin, erythema, and infusionrelated symptoms, such as fever, chills, and severe vomiting. It was hypothesised that Scandinavian people might be more sensitive to Abelcet than those from the UK and the USA 2, 3 and other colleagues were encouraged to report their experiences.
In December 1998 at the University Hospital in Uppsala, 21 patients had been treated with Abelcet since the drug was licensed in Sweden in May 1996. There were eight females and 13 males with a median age of 42 years (range 16-66 years). All except three were Scandinavian. The others came from Bangladesh (n = 1) and the former Yugoslavia (n = 2). Underlying diseases in these patients were acute myeloid leukaemia (n = 9), chronic myeloid leukaemia (n = 7), unclassified myeloproliferative disease (n = 1), aplastic anaemia (n = 2), sarcoidosis (n = 1), and Goodpasture's syndrome (n = 1). Fifteen patients had undergone transplantation: renal transplantation in two, allogeneic bone marrow transplantation in 12, and autologous stem cell transplantation in one patient. Six patients were treated with chemotherapy. Cyclosporin A was concomitantly given to 13 patients.
Seven patients had culture-proven infection with Aspergillus (n = 6) or Mucor (n = 1). Eleven neutropenic patients with pulmonary infiltrates or sinusitis, not responding to antibiotic therapy and with possible aspergillosis, were given Abelcet as empirical therapy. The other three patients had a presumed disseminated invasive fungal infection.
Sixteen patients had had preceding treatment with conventional amphotericin B (Fungizone) but because of nephrotoxicity or acute infusion-related symptoms, the treatment was changed to Abelcet. In four patients, fungal therapy was initiated with Abelcet because of pre-existing renal insufficiency and in one patient AmBisome was given prior to Abelcet for the same reason. The doses given varied from 1.1 mg/kg/day to 5.1 mg/kg/day with a mean dose of 4.1 mg/kg/day. Total dose ranged from 0.37 g to 23 g with a median of 3.5 g. The treatment was given for a median of 20 days with a range from 3 to 77 days.
Four of the patients died during treatment and primary cause of death was the underlying disease in two cases and in two patients mainly an intractable Aspergillus infection.
Abelcet was discontinued in 1/21 (5%) patient due to painful infusion-related paresthesiae in the hands and arms on treatment days 7-9. Treatment was continued with AmBisome, and the symptoms disappeared. Nephrotoxicity, defined as an increase of 100% or more from baseline serum creatinine, was seen in 2/20 (10%) patients. In one patient, concomitantly also treated with meronem, foscarnet, ganciclovir and acyclovir, serum creatinine increased from 47 to 134 mol/l after 13 days. In the other patient, serum creatinine increased from 97 to 201 mol/l 9 days later, shortly before death. When all 21 patients were included into the calculations, there was an increase in serum creatinine of 14 ± 64 mol/l (mean ± s.d.) from a baseline value of 155 ± 102 mol/l.
The bilirubin level increased more than 100% from baseline in four patients. An increase in ALAT of similar magnitude was seen in three patients. However, a reduction of ALAT values of 50% or more was seen in two patients. A doubling of alkaline phosphatase values was seen in five patients and a reduction of more than 50% in one.
Acute toxic side-effects, such as fever and/or chills were seen in 9/21 (43%) patients but in all of them the symptoms disappeared after a few days of continued Abelcet therapy. In six patients suffering from chills, pethidine (meperidine) was given with excellent effect and thereafter it was given as prophylaxis for some time in five of them. We did not see erythema, severe vomiting, back pain, lowered pO 2 , or haemolysis in any of our patients.
In conclusion, our data do not support the hypothesis that Scandinavian people have more side-effects when treated with Abelcet than those from the UK and USA. 2, 3 The reason for the varying experience between our patients and those reported by Ringdén et al 1 is not obvious from data presented. Underlying diseases differ to some extent but the small variation is not a likely explanation for the observed differences in side-effects.
Among the patients reported by Ringdén et al, 12/19 developed renal insufficiency. In the absence of a definition, this is somewhat difficult to evaluate. Nephrotoxicity was patients defined as an increase of Ͼ100% or more from baseline serum creatinine in our patients. Mean baseline creatinine in their patients was 85 mol/l, while in our patients it was higher. However, if nephrotoxicity in our patients had been defined as an increase in creatinine of Ͼ85 mol/l, only one more patient with a baseline serum creatinine of 156 mol/l would have been classified as having nephrotoxicity.
Even if the mechanism for renal toxicity includes renal hypoperfusion and tubular toxicity, the development of renal damage is gradual, and in most cases renal insufficiency develops over several weeks and is mainly associated with the accumulated dose of amphotericin B.
4,5 Considering a median duration of Abelcet therapy of 3 days, the increase in creatinine must in most cases have been very rapid, either indicating a new mechanism for amphotericin B toxicity or that other factors, such as infection, underlying disease, or concomitant medication might be responsible. There was no information about preceding amphotericin B treatment in the report by Ringdén et al and if no treatment was given, it cannot be excluded that this might be of importance. As was also the case in the UK and USA trials, the majority of our patients had received conventional amphotericin B for a varying period of time before treatment with Abelcet. Thus nephrotoxicity data in patients whose kidneys have not been exposed to amphotericin B are somewhat limited and need further investigation. On the other hand, it is difficult to speculate how preceding amphotericin B treatment would reduce the nephrotoxicity of Abelcet.
Amphotericin B infusion-related reactions are most pronounced at the beginning of therapy and tend to level off after repeated administration. If no preceding treatment with conventional amphotericin B was given to the patients reported by Ringdén et al, this might be one explanation for the higher incidence of acute infusion-related reactions among their patients. Furthermore, the medication for treatment of infusion-related reactions seems to differ greatly between our hospitals and this might be of some relevance. The majority of the patients reported by Ringdén et al who were treated for side-effects, presumably acute infusionrelated reactions, were given steroids, while our patients were given pethidine. In our experience, pethidine given as treatment or premedication for Abelcet or conventional amphotericin B has in most cases a very good effect on acute infusion-related symptoms, such as fever and chills. If pethidine is not effective, aniline derivatives or antihistaminic drugs may be tested before a change to AmBisome is made. Steroids are not given. Besides a negative impact on the host inflammatory response, steroids have been suggested to have a direct anti-antifungal effect due to binding of the alcoholic OH-group of the steroid to the ergosterol reacting part of the amphotericin B molecule, rendering
Response to Dr Furebring
Dr Furebring and co-workers have reported the lowest incidence found to date of side-effects using amphotericin B lipid complex (Abelcet) in 21 mainly Scandinavian patients, where the drug was discontinued in only one (5%) due to painful infusion-related paraesthesia in the hands and arms. In contrast, our study at Huddinge Hospital, Huddinge, Sweden, and at Rigshospitalet, Copenhagen, Denmark, showed that Abelcet had to be discontinued in 14/19 (74% of the patients) due to side-effects. Two patients developed life-threatening toxicity. Most reports have shown fewer side-effects from Abelcet, in accordance with the report from Uppsala. [1] [2] [3] This might indicate that Abelcet is a uniformly safe drug with little toxicity. However, severe side-effects have also been noted by other clinicians, although not yet reported. For instance, Dr Mineishi and colleagues from Japan have seen liver failure with Abelcet (personal communication). Since only a few patients have been reported by single centres, the high variability of side-effects from Abelcet may be due to amphotericin B unavailable to interact with the fungal cell membrane. 6 Finally, there is no information in the report by Ringdén et al on whether the recommended test dose of 1 mg was given prior to therapy. Such a dose might have revealed the tendency to pulmonary reaction seen in the 32-yearold male.
In summary, our data do not support the hypothesis that Scandinavian people react differently to Abelcet than do those from the UK and the USA. M Furebring 1 1 chance. However, recently, a randomized study was presented at 'The Focus on Fungal Infections' Meeting in San Diego in March this year. 4 The head-to-head study compared 5 mg/kg/day of Abelcet with both 3 mg/kg/day and 5 mg/kg/day of AmBisome in 244 evaluable patients. AmBisome was significantly safer at both dose levels than Abelcet regarding nephrotoxicity and acute, infusionrelated reactions, such as chills and rigors, fever and hypoxia. The drug was discontinued due to toxicity in 21 (13%) of the AmBisome-treated patients, compared to 25 (32%) of the Abelcet patients. These 32% are between the 5% reported by the Uppsala group and the 74% in our patients.
Regarding the specific comments about our study, renal toxicity in 12/19 Abelcet patients was defined as an increase of Ͼ100% from the pre-Abelcet serum creatinine level. None of our patients had received amphotericin B treatment prior to Abelcet unlike the situation in other reported studies, where most of the patients received conventional amphotericin B before treatment with Abelcet. [1] [2] [3] It is probable that this influenced the evaluation of side-
